文献速递头颈外科

姑息期头颈癌患者的决策冲突研究

Decisional Conflict in Palliative Head and Neck Cancer Patients.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-04-27

这项前瞻性队列研究纳入104例进入姑息期的头颈癌患者,分为不可治愈组72例和放弃治愈性治疗组32例。结果显示,不可治愈组临床显著决策冲突(DCS≥25)比例为65.3%,放弃治疗组为43.8%,两组差异显著。不可治愈组有3个生活质量域、放弃治疗组有6个生活质量域在有无临床显著决策冲突间表现出较大差异。

要点

  • 姑息期头颈癌患者决策冲突常见,不可治愈组临床显著决策冲突比例高于放弃治愈性治疗组。
  • 不可治愈组中65.3%存在临床显著决策冲突,放弃治愈性治疗组为43.8%。
  • 在放弃治愈性治疗的患者中,肿瘤I/II期显著预测较少的决策冲突。

核心结论

  • 姑息期头颈癌患者中临床显著决策冲突较常见,且不可治愈组比放弃治愈性治疗组更普遍。
  • 两组患者决策冲突的差异提示需要针对不同队列提供定制化咨询以支持以患者为中心的照护。

研究设计与样本

  • 前瞻性队列研究,在三级癌症中心开展,纳入2022年9月至2024年3月进入姑息期的头颈癌患者。
  • 共纳入104例患者,其中不可治愈头颈癌72例,放弃治愈性治疗32例。
  • 决策冲突采用决策冲突量表(DCS)测量,生活质量采用EORTC QLQ-C15-PAL评估。

主要发现

  • 不可治愈头颈癌患者中47例(65.3%)存在临床显著决策冲突(DCS评分≥25)。
  • 放弃治愈性治疗患者中14例(43.8%)存在临床显著决策冲突,两组差异显著。
  • 在放弃治愈性治疗的患者中,肿瘤I/II期显著预测较少的决策冲突。
  • 不可治愈头颈癌患者中,有无临床显著决策冲突在3个生活质量域表现出较大差异;放弃治愈性治疗患者中为6个生活质量域。

关键数值与推荐

  • 临床显著决策冲突定义为DCS评分≥25。
  • 不可治愈头颈癌组临床显著决策冲突比例为65.3%(47/72)。
  • 放弃治愈性治疗组临床显著决策冲突比例为43.8%(14/32)。

临床怎么用

  • 对姑息期头颈癌患者应常规评估决策冲突,尤其不可治愈患者风险更高。
  • 根据患者所属队列(不可治愈 vs 放弃治愈性治疗)提供定制化咨询,以减少决策冲突。
  • 在放弃治愈性治疗的患者中,早期肿瘤分期可能提示较低决策冲突风险,可据此调整沟通策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Head and neck cancer (HNC) patients may be subject to decisional conflict (DC). However, research on DC in the palliative phase remains limited. The primary objective of this study was to assess and describe DC among patients with HNC in the palliative phase and explore the association between clinically significant DC and quality of life (QoL). STUDY DESIGN: Prospective cohort study. SETTING: Tertiary cancer center. METHODS: Patients with HNC entering the palliative phase between September 2022 and March 2024 were eligible. Patients were assessed in 2 cohorts: incurable HNC and refraining from curative treatment. DC was measured using the Decisional Conflict Scale (DCS). Other measures included patient, tumor, and palliative characteristics, and the EORTC QLQ-C15-PAL for QoL. RESULTS: Of 104 included patients, 72 patients had incurable HNC and 32 refrained from curative treatment. Clinically significant DC (score ≥25) was observed in 47 incurable HNC patients (65.3%) and 14 patients who refrained from curative treatment (43.8%), which was a significant difference. Tumor stage I/II was significantly predictive of less DC in patients who refrained from curative treatment. Three QoL domains showed large differences for incurable HNC patients when differentiating for clinically significant DC, and 6 for those who refrained from treatment. CONCLUSION: This study provides valuable insights into DC among palliative HNC patients. Clinically significant DC was more common in patients with incurable HNC than those who refrained from curative treatment. These findings highlight key differences between the cohorts, underscoring the need for tailored counselling to support patient-centered care.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. van den Besselaar BN, Herkendaal AF, Sewnaik A, et al. Decisional Conflict in Palliative Head and Neck Cancer Patients. Otolaryngol Head Neck Surg. 2026. PMID: 42037473. doi:10.1002/ohn.70256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。